Bronchiolitis Obliterans Syndrome Clinical Trial
Official title:
Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants Recipients
Electrical impedance tomography (EIT) is non-invasive and provides functional imaging of the lung and it could be a useful tool to diagnose chronic lung allograft dysfunction (CLAD) and specially Bronchiolitis Obliterans Syndrome (BOS). Hence, for this study, the investigators aim to show that EIT would provide an accurate diagnostic CLAD with an ability to to distinguish BOS from Restrictive Allograft Syndrome (RAS) and to stage BOS accurately when compared to FEV1 the current gold standard. The investigators are also aiming to provide physiological data in lung transplant recipients with chronic rejection.
Lung transplantation is the only treatment option available for patients affected by
end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis
or idiopathic pulmonary fibrosis, not responding to maximal medical therapy. Despite the
advance in the surgical techniques, immunosuppression treatment and prevention of acute
cellular rejection episodes as well as opportunistic infections, the long terms outcomes
following lung transplant remain unsatisfactory. Chronic lung allograft dysfunction (CLAD) is
the first cause of long term mortality in lung transplant recipients responsible of 5 years
mortality post-surgery of 50%. CLAD can lead to chronic respiratory failure and can presents
in two different phenotypes: Restrictive forms of CLAD were all lung volumes are decreased
(commonly called RAS, Restrictive Allograft Syndrome) that has been recently associated with
antibodies mediated rejection. A more common form of obstructive CLAD has been identified as
the well-known and defined Bronchiolitis Obliterans Syndrome (BOS). In patients with BOS, the
progressive obliteration and a narrowing of the distal airways result in breathlessness,
airflow obstruction and air trapping.
Currently, Forced Expiratory Volume at 1 second (FEV1) measurement is the gold standard to
assess BOS severity. This test is non invasive and easily performed at bedside. Thus, it only
gives a broad idea of the regional consequences of BOS as may be influenced by large airway
obstructions. Chest computed tomography (CT) gives more detailed imaging of the regional
consequences of BOS but is time-consuming and expose patients to radiations. Others imaging
techniques such as ventilation/perfusion scintigraphy have been studied but cannot be
performed at bedside.
As to date there is no curative treatment for BOS, preventive treatments such as long term
azithromycin, bronchodilators, inhaled steroids or plasmapheresis have to be started at early
stage of the disease to improve outcomes for the recipients Electrical impedance tomography
(EIT) is a new technology that involves wearing a belt of sensors around the chest that
provides information on how well the lungs are being filled with air by the ventilator. It
allows the assessment of these differences, which previously required the use of invasive
equipment to obtain. Information is gained by repeatedly injecting small alternating electric
currents (usually 5 mA) at high frequency of 50 - 80 kHz through a system of skin electrodes
(usually 16) applied circumferentially around the thorax in a single plane between the 4th
and 6th intercostal space. While an adjacent pair of electrodes 'injects' the current
('adjacent drive configuration'), all the remaining adjacent passive electrode pairs measure
the differences in electric potential. A resistivity (impedance) image is reconstructed from
this data by a mathematical algorithm using a two dimensional model and a simplified shape to
represent the thoracic cross-section.
The resulting image possesses a high temporal and functional resolution making it possible to
monitor dynamic physiological phenomena (e.g. delay in regional inflation or recruitment) on
a breath by breath basis. It is important to realize that the EIT images are based on image
reconstruction techniques that require at least one measurement on a well-defined reference
state. All quantitative data are related to this reference and can only indirectly quantify
(relative) changes in local lung impedance (but not absolute).
EIT can be used in mechanically ventilated patients to assess recruitment and to optimise
ventilator settings to reduce risk of iatrogenic ventilator associated lung injury. To date,
EIT has never been used in lung transplant recipients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01807975 -
Forced Oscillation Versus Spirometry in Diagnosing Post Pulmonary Transplant Bronchiolitis Obliterans Syndrome
|
N/A | |
Completed |
NCT01009619 -
Azithromycin in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Recruiting |
NCT04391335 -
Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children
|
||
Recruiting |
NCT05922761 -
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
|
Phase 2 | |
Recruiting |
NCT05250037 -
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
|
||
Enrolling by invitation |
NCT04039347 -
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
|
Phase 3 | |
Recruiting |
NCT05413356 -
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
|
Phase 2 | |
Recruiting |
NCT00774449 -
Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation
|
N/A | |
Terminated |
NCT03978637 -
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT02316392 -
Imaging and Understanding BOS in Lung Transplantation
|
||
Completed |
NCT00528853 -
Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation
|
N/A | |
Recruiting |
NCT06018766 -
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
|
Phase 2 | |
Recruiting |
NCT02669251 -
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT03072849 -
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation
|
N/A |